A Blood Test Costing 120 Pounds Could Detect the 12 Most Common Cancers: Continuing Hope for Early Diagnosis

Early cancer diagnosis is one of the most critical determinants of treatment success. Health authorities worldwide are seeking innovative ways to detect cancer earlier. According to an October 6, 2024 report in The Guardian , the UK government announced funding to make a new blood test capable of detecting the 12 most common cancers available to the public, marking an important step in this effort. At a cost of just 120 £ (approximately 5,400 TRY), the test will enable early diagnosis of common cancers. Why does this development offer such hope, and what impact could it have on the healthcare system?

The Galleri Test: Advanced Early Detection Technology

This new blood test, commercially known as “Galleri,” was developed by the US-based company GRAIL. It aims to detect abnormal DNA fragments released into the blood by tumor cells. This DNA is called “cell-free DNA” (cfDNA), and Galleri uses modern genetic sequencing technology and artificial intelligence to detect chemical changes in cfDNA that originate in cancer cells and are absent from healthy cells. Galleri is therefore a multicancer early diagnosis test (MCED = multi cancer early diagnosis test).

RELATED TOPICS:

• What Is a Multicancer Early Detection Test? What Do True, False, Positive, and Negative Results Mean?
• The Difficulty of Proving the Benefits of Multicancer Early Detection Tests: An NEJM Article

The Lifesaving Importance of Early Diagnosis

Because cancer often causes no symptoms in its early stages, many people discover the disease only when it is advanced. This adversely affects treatment success and the cost of care to the healthcare system. Detecting different cancers at an early stage through a blood test could not only improve the chances of treatment but also dramatically increase treatment success rates.

For example, in common cancers such as breast or prostate cancer, early diagnosis brings treatment forward considerably and allows patients to maintain their quality of life. If this new blood test enters widespread use soon, the important opportunity offered by early diagnosis could become accessible to many more people.

How the Test Works and Its Potential Impact

Using a simple blood sample, the Galleri test analyzes blood biomarkers to detect different cancer types at an early stage. According to GRAIL's reports, it has the potential to detect more than 50 cancers and has a false-positive rate of 0.5%. This means that approximately 1 in 200 people could receive a positive result despite not having cancer.

The UK's National Health Service (NHS = National Health Service) states that, if the test becomes widespread, earlier diagnosis and treatment could dramatically reduce the burden on the healthcare system. Reducing advanced cancer cases, whose treatment costs are particularly high, could enable the NHS to make substantial savings.

Galleri Clinical Research and the NHS Trial

Galleri is currently being tested in a large clinical trial in cooperation with the NHS in the United Kingdom. The trial includes 140,000 people aged 50-77, who undergo annual blood tests for two years. Participants are randomized into two groups: half have their blood samples analyzed with Galleri, while samples from the other half are stored for future analysis.

The final results of Galleri's large trial involving 1 million people will be announced in 2026, and the NHS plans to make a decision based on them. Reimbursement is therefore not certain at present, although a step in that direction may potentially be taken.

Meanwhile, the UK government continues to invest significantly in health technologies and has announced a new funding package of 148 million £. This includes collaboration with universities and health services to develop early diagnosis technologies such as Galleri. Health Secretary Wes Streeting stated that such investments offer considerable hope for early cancer diagnosis.

In summary, although the NHS has not yet included Galleri in reimbursement, large studies of its effectiveness and potential benefits continue, and it may become more widely available in the future. Current developments are promising, but final data are awaited before definite decisions.

An Overview of Benefits for Society and Individuals

The new blood test could provide substantial benefits for society. Cancer seriously affects not only the person with the disease but also their family, social circle, and healthcare system. Early diagnosis allows patients to receive earlier and more effective treatment and also offers psychological hope.

From a societal perspective, lower treatment costs for cases diagnosed early would reduce the economic burden on healthcare systems. This would allow resources to be used more effectively and more funding to be allocated to other diseases. At a cost of 120 £, this blood test could therefore be seen as a major investment in the healthcare system.

Conclusion: Early Diagnosis Is a Key Tool Against Cancer

Early diagnosis is one of the greatest advantages in the fight against cancer. The UK government's commitment to funding this new blood test is an important step. Widespread use of Galleri has the potential to save millions of lives and substantially benefit the healthcare system. More extensive future use of advanced technologies in cancer screening could open the door to a much more hopeful era in cancer care.

*

Types of MCED Tests: Names, Technologies, and Target Cancers

The table below shows the names of MCED tests developed by various companies, the technologies they use, and the cancers they target: